Ares Capital vs Ryan Specialty
Large lender financing middle market companies vs US specialty insurer and distribution platform. Which is the better buy for your portfolio in September 2026? Plain-English answer below.
Ares Capital is the largest publicly traded business development company in the US, deploying billions into middle-market credit with disciplined underwriting, while Ryan Specialty has carved out a specialty insurance distribution niche that compounds beautifully through acquisitions. Both businesses thrive on complexity that scares off generalist competitors. The Ares Capital vs Ryan Specialty comparison breaks down fee structures, credit quality, return on equity, and what differentiates a great alternative finance platform from a great specialty brokerage.
Ares Capital is the largest publicly traded business development company in the US, deploying billions into middle-market credit with disciplined underwriting, while Ryan Specialty has carved out a sp...
Investment Analysis
Ares Capital
ARCC
Pros
- Ares Capital is the largest publicly traded Business Development Company by market capitalization, providing scale advantages and market leadership.
- The company has delivered a 13% annualized total shareholder return since its 2004 IPO, reflecting strong historic performance.
- It generates steady income with a high dividend yield around 9.4%, supported by investments in senior secured loans and diversified debt/equity assets.
Considerations
- Returns on assets and equity are moderate at about 4.9% and 10.3% respectively, indicating modest profitability.
- The share price has shown modest volatility with a year-to-date decline and a current valuation near book value, suggesting limited price appreciation potential.
- Its exposure to middle-market loans introduces credit risk sensitive to economic cycles and interest rate changes, posing potential downside risks.
Ryan Specialty
RYAN
Pros
- Ryan Specialty Holdings operates in a growing specialty insurance services segment across multiple international regions providing revenue diversification.
- The company recently issued $500 million in senior secured notes, indicating access to capital for potential growth investments.
- Forward price-to-earnings ratio of 24.4 suggests market expectations for earnings improvement compared to its very high trailing P/E of 257.
Considerations
- Ryan Specialty reported a net loss in the trailing twelve months with an EPS of -0.10, highlighting current profitability challenges.
- Its stock trades with a very high P/E ratio, indicating elevated valuation risk if growth or earnings improvement disappoints.
- The insurance specialty sector can be cyclical and exposed to regulatory and claims volatility, introducing uncertainty around earnings stability.
Buy ARCC or RYAN in Nemo
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
